The Clinical safety of Vonoprazan in the Gastric Acid Management

Vonoprazan is approved for various clinical indications, including gastric and duodenal ulcers, erosive esophagitis, Helicobacter pylori eradication, PPI-resistant reflux esophagitis, prevention for recurrence in nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin ulcer, and prevention of endoscopic submucosal dissection-induced ulcer.^3,4

Coming to the safety of the molecule, a meta-analysis revealed that vonoprazan-containing regimens significantly outperformed PPI-containing regimens for Helicobacter pylori eradication (p<0.0001) and also demonstrated significantly lower adverse event (AE) occurrence at 26.4% in vonoprazan groups compared to 33.3% in PPI groups (p=0.008).¹ Another prospective observational study involving 1,642 patients with gastrointestinal disorders indicated efficacy of vonoprazan in amelioration of the complications with only 2.3% of patients experiencing AEs which were mild in intensity.⁵

Let’s hear to what Prof. Hidekazu Suzuki has to say about the clinical safety of Vonoprazan in the gastric acid management.

 

 

Conclusion

Vonoprazan, a P-CAB, provides better acid suppression compared to PPIs.¹ Along with its significantly higher efficacy in gastrointestinal disorders compared to PPIs, vonoprazan has been reported to be safe with significantly lower AE occurrence.^1,5

References

1. Dong SQ, Singh TP, Wei X, et al. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? Helicobacter. 2017;22(6):e12438.
2. Scarpignato C, Hunt RH. Acid suppressant therapy: A step forward with potassium-competitive acid blockers. Curr. Treat. Options Gastroenterol. 2021;19:94–132.
3. Veererathinakumar NK, Ananthy V, Codi RS, et al. Potassium-competitive acid blocker: A newer target in the treatment of acid peptic disorder. SBV J. Basic Clin. Appl. Health Sci. 2023;6(2):33–38.
4. Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.
5. Abbasi A, Siddiqui SA, Ram B, et al. Real-world evidence to evaluate the efficacy and safety of vonoprazan in gastrointestinal disorders in the Pakistani population. Cureus. 2023;15(11):e48994.

For the use of a registered medical practitioner, hospital or laboratory only.

LMRC Code: GGI-CO-A1-AQS-300041558-APPEMC-G24-1181 DOI of 15/07/24 and DOE of 15/08/24